百利天恒：公司药品纳入突破性治疗品种名单

Core Viewpoint - The company, Bai Li Tian Heng, has announced that its self-developed drug, iza-bren (EGFR×HER3 dual antibody ADC), has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients [2] Group 1 - The drug iza-bren is described as a first-in-class and new concept therapy, indicating its innovative nature in the oncology field [2] - The drug has reached the III phase of clinical trials, showcasing its advanced development stage [2] - The inclusion in the breakthrough therapy list signifies a potential acceleration in the drug's approval process and market entry [2]